Ed Clarke
Overview
Explore the profile of Ed Clarke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kampmann B, Pley C, Strandmark J, Leigh M, Ndow P, Clarke E, et al.
Wellcome Open Res
. 2025 Feb;
9:733.
PMID: 39935766
Background: Yellow fever (YF) is a mosquito-borne and recently re-emerging viral haemorrhagic fever endemic to sub-Saharan Africa and South America. A highly effective vaccine against YF is licensed and recommended...
2.
Peno C, Jagne Y, Clerc M, Balcazar Lopez C, Armitage E, Sallah H, et al.
Lancet Microbe
. 2025 Jan;
6(3):100971.
PMID: 39832517
Background: Live attenuated influenza vaccines (LAIVs) alter nasopharyngeal microbiota in adults. It is poorly understood why LAIV immunogenicity varies across populations, but it could be linked to the microbiome. We...
3.
Osei I, Schmidt-Chanasit J, Licciardi P, Secka O, DAlessandro U, Salaudeen R, et al.
Vaccine
. 2025 Jan;
47:126712.
PMID: 39798436
Introduction: Because booster doses of pneumococcal conjugate vaccine (PCV) may be given at a similar time to yellow fever vaccine (YF), it is important to assess the immune response to...
4.
Bruce A, Umesi A, Bashorun A, Ochoge M, Yisa M, Obayemi-Ajiboye D, et al.
Trials
. 2024 Sep;
25(1):579.
PMID: 39223604
Background: Despite Africa's significant infectious disease burden, it is underrepresented in global vaccine clinical trials. While this trend is slowly reversing, it is important to recognize and mitigate the challenges...
5.
Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, et al.
Lancet
. 2024 May;
403(10439):1879-1892.
PMID: 38697170
Background: Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data...
6.
Ochoge M, Futa A, Umesi A, Affleck L, Kotei L, Daffeh B, et al.
Lancet
. 2024 Feb;
403(10432):1164-1175.
PMID: 38402887
Background: Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of circulating vaccine-derived polioviruses....
7.
Zemsi A, Nekame L, Mohammed N, Batchilly E, Dabira E, Sillah S, et al.
Ther Innov Regul Sci
. 2024 Jan;
58(3):395-403.
PMID: 38285370
A clinical trial is any research on human subjects that involves an investigational medicinal product or device. Investigational medicinal products include unlicensed drugs or drugs used outside the product license...
8.
Kotei L, Clarke E
Lancet Infect Dis
. 2024 Jan;
24(4):337-339.
PMID: 38246192
No abstract available.
9.
Bashorun A, Kotei L, Jawla O, Jallow A, Saidy A, Kinteh M, et al.
Lancet Infect Dis
. 2024 Jan;
24(4):417-426.
PMID: 38237616
Background: Novel oral polio vaccine type 2 (nOPV2) has been used to interrupt circulating vaccine-derived poliovirus type 2 outbreaks following its WHO emergency use listing. This study reports data on...
10.
Clarke E, Alderson M, Tapia M
N Engl J Med
. 2023 Aug;
389(6):577-578.
PMID: 37590459
No abstract available.